Pharma channel feed

Paul Hud­son faces down French unions in fight to re­struc­ture Sanofi

5 years ago

As­traZeneca keeps the ball rolling on Dai­ichi-part­nered En­her­tu, pick­ing up 2nd in­di­ca­tion in gas­tric can­cer

5 years ago
FDA+

Eli Lil­ly re-ups di­ver­si­ty pledge, pitch­ing in $30M to ven­ture fund for mi­nor­i­ty-owned health­care firms

5 years ago
Financing

Am­gen tops cost watch­dog's price gougers list based on 'un­sup­port­ed' in­creas­es for En­brel with­out mean­ing­ful da­ta

5 years ago

#JPM21: Al­bert Bourla pre­pares Pfiz­er to set­tle in to next phase post-Up­john, but that does­n't mean he's rul­ing out deals

5 years ago
People

What can a 157-year-old phar­ma gi­ant bring to the ta­ble of cell and gene ther­a­pies? Quite a bit, Bay­er says

5 years ago
Cell/Gene Tx

Sanofi has a name for its in­gre­di­ents spin­off, taps Cen­tri­ent head Karl Rot­thi­er as first CEO

5 years ago

Trump's HHS con­tin­ues to as­sert au­thor­i­ty over FDA in twi­light of his pres­i­den­cy, im­ple­ment­ing new drug time­line rules

5 years ago
FDA+

Af­ter pan­dem­ic-re­lat­ed dis­rup­tions, will 2021 bring about a re­newed spot­light on R&D? A CFO sur­vey says yes

5 years ago

Bio­phar­ma lead­ers con­demn mob vi­o­lence on Capi­tol Hill, look­ing to close Trump's chaot­ic chap­ter in Amer­i­can his­to­ry

5 years ago

New year, new me: Pfiz­er aban­dons icon­ic 'blue pil­l' lo­go in fa­vor of sleek­er — if more am­bigu­ous — new de­sign

5 years ago

So why is Alex­ion pay­ing $100M for a PRV as As­traZeneca lines up their $39B buy­out?

5 years ago
Deals

Re­call re­port: Nos­trum ex­pands re­call of di­a­betes drug met­formin af­ter car­cino­gen con­cerns

5 years ago
FDA+

Bris­tol My­ers Squibb walks on Op­di­vo's FDA nod for small-cell lung can­cer af­ter mid­dling OS da­ta could­n't back ap­proval

5 years ago
FDA+

EU reg­u­la­tor says As­traZeneca ap­proval not im­mi­nent, even as Pas­cal So­ri­ot teas­es stronger da­ta

5 years ago
Coronavirus

With pipeline set­backs mount­ing, Unit­ed snares pri­or­i­ty vouch­er for in­haled for­mu­la­tion of PAH med Ty­va­so

5 years ago
FDA+

A fed­er­al judge blocks Don­ald Trump's 'most fa­vored na­tion' drug pric­ing plan as the lease runs out on the White House

5 years ago

Af­ter mul­ti­ple set­backs, Bris­tol My­ers scut­tles Op­di­vo pro­gram for brain tu­mor pa­tients af­ter fail­ing to pro­long lives

5 years ago
R&D

Twist Bio­science plots its 'fac­to­ry of the fu­ture' in Ore­gon, seeks to ex­pand syn­thet­ic DNA client base

5 years ago
Manufacturing

Mi­nor­i­ty in­vestor Wa­ter­Mill suc­ceeds in ac­tivist at­tack of Zio­pharm, win­ning two board seats and re­moval of chair­man

5 years ago

Glax­o­SmithK­line's Benlysta earns first FDA ap­proval for lu­pus nephri­tis as com­peti­tors wait in the wings

5 years ago
FDA+

Macro­Gen­ics scores first FDA ap­proval with breast can­cer med Mar­gen­za in third-line pa­tients

5 years ago
FDA+

No­var­tis sets eyes on new­ly-ac­quired Alex­ion with break­through tag for rare dis­ease hope­ful ip­ta­co­pan

5 years ago
FDA+

No­var­tis earns ad­com­m's vote of sup­port in come­back FDA re­view for En­tresto in sought-af­ter heart fail­ure pa­tients

5 years ago
FDA+
First page Previous page 247248249250251252253 Next page Last page
A service from the Financial Times